Understand the source comparison
Cartalax Side Effects Long Term Research: Peptide Comparison
Cartalax (Ala-Glu-Asp) 10–30 days <5% (mild GI effects) Minimal. One 2-year observational cohort, no controlled trials Lack of Phase IV surveillance; no FDA approval pathway Short-term safety is well-established; long-term risk profile remains speculative due
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cartalax (Ala-Glu-Asp)
- 10–30 days
- <5% (mild GI effects)
- Minimal. One 2-year observational cohort, no controlled trials
- Lack of Phase IV surveillance; no FDA approval pathway
- Short-term safety is well-established; long-term risk profile remains speculative due to research funding gaps
- BPC-157
- 14–28 days
- <3% (injection site reactions)
- Moderate. Multiple animal studies, limited human longitudinal data
- Human trials are sparse; most data from veterinary or animal models
- Frequently used off-label but lacks robust human long-term tracking
- Thymosin Beta-4
- 4–12 weeks
- <8% (mild systemic reactions)
- Moderate. Post-market use in equine medicine provides indirect data
- Cross-species extrapolation introduces uncertainty
- Longer intervention windows than Cartalax; still lacks dedicated human safety cohorts
- Epithalon
- 10–20 days per cycle
- <2% (headache, sleep disturbance)
- Minimal. Cycles repeated annually in small cohorts, no formal tracking
- Almost no published Western trials; Eastern European data only
- Exceptional short-term tolerability; long-term effects are purely theoretical
- This table underscores a consistent pattern across bioregulatory peptides: excellent short-term safety, minimal long-term validation. Cartalax fits squarely in this category. Safe within documented windows, unknown beyond them.